These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21499787)

  • 21. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful use of paliperidone in a clozapine-resistant schizophrenic patient.
    Hsieh TH; Liu CT
    J Neuropsychiatry Clin Neurosci; 2013; 25(2):E36. PubMed ID: 23686056
    [No Abstract]   [Full Text] [Related]  

  • 23. A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.
    Schreiner A; Bergmans P; Cherubin P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Hargarter L
    Clin Ther; 2014 Oct; 36(10):1372-88.e1. PubMed ID: 25444566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials.
    Ortega I; Perez-Ruixo JJ; Stuyckens K; Piotrovsky V; Vermeulen A
    J Clin Pharmacol; 2010 Mar; 50(3):293-310. PubMed ID: 20056804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using paliperidone as a monotherapeutic agent on a schizophrenic patient with cirrhosis of the liver.
    Chou HW; Chen CL
    J Neuropsychiatry Clin Neurosci; 2013; 25(1):E37. PubMed ID: 23487226
    [No Abstract]   [Full Text] [Related]  

  • 26. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia.
    Yang J; Ko YH; Paik JW; Lee MS; Han C; Joe SH; Jung IK; Jung HG; Kim SH
    Schizophr Res; 2012 Feb; 134(2-3):226-31. PubMed ID: 22133906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.
    Kane J; Canas F; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Schizophr Res; 2007 Feb; 90(1-3):147-61. PubMed ID: 17092691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No change of the lipid profile under the control of ApoE gene polymorphism in schizophrenics under paliperidone treatment.
    Kao WT; Chang CL; Chen YL; Lung FW
    Psychiatr Q; 2014 Dec; 85(4):487-96. PubMed ID: 25085446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of paliperidone extended release on the symptoms and functioning of schizophrenia.
    Huang MW; Yang TT; Ten PR; Su PW; Wu BJ; Chan CH; Lan TH; Liu IC; Chiu WC; Li CY; Cheng KS; Yeh YC
    BMC Clin Pharmacol; 2012 Jan; 12():1. PubMed ID: 22225965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.
    Owen RT
    Drugs Today (Barc); 2007 Apr; 43(4):249-58. PubMed ID: 17460786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
    Kim SW; Chung YC; Lee YH; Lee JH; Kim SY; Bae KY; Kim JM; Shin IS; Yoon JS
    Int Clin Psychopharmacol; 2012 Sep; 27(5):267-74. PubMed ID: 22809972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.
    Coppola D; Liu Y; Gopal S; Remmerie B; Samtani MN; Hough DW; Nuamah I; Sulaiman A; Pandina G
    BMC Psychiatry; 2012 Mar; 12():26. PubMed ID: 22455454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
    Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
    Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
    Davidson M; Emsley R; Kramer M; Ford L; Pan G; Lim P; Eerdekens M
    Schizophr Res; 2007 Jul; 93(1-3):117-30. PubMed ID: 17466492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
    Canuso CM; Bossie CA; Amatniek J; Turkoz I; Pandina G; Cornblatt B
    Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication.
    Beck EM; Cavelti M; Kvrgic S; Kleim B; Vauth R
    Schizophr Res; 2011 Oct; 132(1):42-9. PubMed ID: 21820875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reliability and Validity of the Short Version of Udvalg for Kliniske Undersogelser in Antipsychotic Treatment.
    Chen KP; Lung FW
    Psychiatr Q; 2017 Dec; 88(4):787-796. PubMed ID: 28150091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.
    Kwon JS; Kim SN; Han J; Lee SI; Chang JS; Choi JS; Lee HJ; Cho SJ; Jun TY; Lee SH; Han C; Lee KU; Lee KK; Lee E
    Int Clin Psychopharmacol; 2015 Nov; 30(6):320-8. PubMed ID: 26196188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy of paliperidone extended-release tablets in the improvement of social functions in schizophrenics: a randomized and controlled study].
    Wang Y; Li WS; Gu DK; Yang N; Lu Y; Zhang Y; Cao Y; Bai LD
    Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(29):2030-5. PubMed ID: 21029638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical improvement, relapse and treatment adherence with paliperidone palmitate 1-month formulation: 1-year treatment in a naturalistic outpatient setting.
    Di Lorenzo R; Cameli M; Piemonte C; Bolondi M; Landi G; Pollutri G; Spattini L; Moretti V; Ferri P
    Nord J Psychiatry; 2018 Apr; 72(3):214-220. PubMed ID: 29278968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.